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Abstract 
Intestinal failure (IF) is the reduction of gut function or mass below a minimum needed to 
absorb nutrients and fluids, such that patients are dependent on parenteral nutrition (PN). 
Patients with IF have an altered gut microbiome. Our aim was to review and evaluate the 
current evidence on gut microbiome and its metabolic activity as well as its association with 
disease characteristics in adults and children with IF. We performed a PubMed literature 
search for articles published after 2000 using the following terms: intestinal failure, 
microbiome, microbiota, short-chain fatty acids, short bowel syndrome and parenteral 
nutrition. Literature search was restricted to human studies only. The gut microbiome diversity 
is remarkably reduced and community structure is altered with a noticeable over-abundance 
of Proteobacteria, especially the Enterobacteriaceae family. A substantial increase in 
Lactobacillus level is often reported in patients with IF. Gut microbiome characteristics have 
been associated with poor growth, liver disease, D-lactic acidosis and duration of intestinal 
adaptation. Differences in microbiome characteristics have been found between patients on 
PN and those whose guts have adapted and have been weaned off PN. Future research with 
prospective sample collection should explore the value of the gut microbiome as a biomarker 
to guide clinical practice and as a modifiable therapeutic target to optimize outcomes of 
patients with IF. 
 
 
 
  
1. Introduction 
In the first part of this review, we summarize the primary literature looking at the gut 
microbiome characteristics and its association with disease characteristics in patients with 
intestinal failure (IF). In the second part, we discuss future perspectives on the role of the gut 
microbiome in the management of patients with IF, including its potential use as a biomarker 
of intestinal adaptation, prediction of clinical outcomes and as a therapeutic target.  
 
1.1 Intestinal failure 
Intestinal failure is defined as the critical reduction of functional gut mass below the minimum 
needed to absorb nutrients and fluids, such that intravenous supplementation with parenteral 
nutrition (PN) is required to maintain health and/or growth.(1, 2) The intestine is either too 
short, as a consequence of surgical resection or congenital conditions leading to short bowel 
syndrome (SBS), or dysfunctional despite adequate length. Symptoms of IF vary from 
abdominal pain, diarrhea, vomiting, abdominal distension to dehydration and malnutrition. 
Patients with SBS may undergo intestinal adaptation, where the remaining small intestine 
undergoes structural and functional changes to increase its absorptive capacity.(3) This 
process may eventually allow patients to wean off PN and become fully dependent on enteral 
and oral feeding.   
 
1.2 Human microbiome 
It is estimated that the human gastrointestinal tract contains 1014 bacteria.(4, 5) These 
gastrointestinal tract associated microbes are collectively referred to as the gut microbiome. 
Previous studies have detected bacteria prenatally in the placenta, amniotic fluid and also in 
the meconium of newborns.(6-8) Rapid colonization of the gastrointestinal tract starts 
immediately after birth with its immediate composition depending on gestational age, mode of 
delivery and feeding.(9, 10) Formula-fed infants tend to have more Bacteroidetes and fewer 
Actinobacteria and Firmicutes than breast-fed ones.(11) 
 
During the first years of life, the gut is gradually colonized, with genetics, environmental 
factors, diet and the development of the immune system determining the large extent of 
compositional variation among individuals.(12-14) The gut microbiome becomes relatively 
stable in adulthood, with its intra-individual variation being lower than the differences seen 
between different subjects.(14) Bacteria belonging to Firmicutes and Bacteroidetes phyla 
dominate the gut and, to a lesser extent, species from Verrucomicrobia, Proteobacteria and 
Actinobacteria (Figure 1).(15, 16)   
The gut microbiome is important for several functions such as fermentation and 
absorption of nutrients in the colon, development of the immune system, intestinal mucosal 
growth and integrity.(17, 18) There is growing evidence that certain groups of bacteria such 
as Clostridia are important for normal intestinal function and protection against intestinal 
diseases, whereas other pro-inflammatory bacteria, specifically certain species belonging to 
Enterobacteriaceae, are harmful.(19-21)  
The metabolic functional potential of the microbiome is enormous. Short-chain fatty 
acids (SCFA) are perhaps the most important bacterial metabolites and end-products of 
fermentation of non-digestible dietary carbohydrates (i.e. fibre) by anaerobic bacteria. Acetate, 
propionate and butyrate present 90-95% of the SCFA produced in the colon.(22, 23) Although 
fibre is the main contributor, proteins, glycoproteins and peptides from host’s diet and intestinal 
cell turnover can also constitute fermentation substrate.(24) The colon absorbs more than 
95% of SCFA(25), contributing to an estimate of 5-10% of the human energy 
requirements.(26) Moreover, they stimulate vascular flow and motility, increase sodium 
absorption, affect cell proliferation and differentiation, and promote apoptosis of carcinogenic 
cells.(22, 27, 28) Not all bacteria produce the same SCFA and their molar concentration and 
proportional ratio in the colon depends also on the type and composition of fermentable 
carbohydrate.(29)  
 
2. Methods 
A PubMed literature search was performed, for articles published after 2000, using the 
following terms: intestinal failure, microbiome, microbiota, short-chain fatty acids, short bowel 
syndrome and parenteral nutrition. Literature search was restricted to human studies only. 
References from the selected manuscripts were searched for additional relevant publications. 
In addition, the literature was evaluated for associations with disease characteristics.  
 
3. Results 
3.1 Factors influencing the microbiome in IF 
Several factors can influence the gut microbiome in patients with IF (Figure 2). 
Gastrointestinal anatomy and physiology play an important role. Extensive small bowel 
resection alters intestinal environment, including luminal pH and oxygen concentration, and 
enterohepatic circulation of bile acids.(30, 31) A study in mice showed that small bowel 
resection caused Lactobacillus overgrowth, even when not receiving PN.(32) Korpela et 
al.(33) found that the length of the remaining small bowel was negatively associated with the 
abundance of Lactobacillus plantarum spp. Removal of the ileocecal valve predisposes the 
small intestine to overgrowth of bacteria and removal of the ileum may lead to bile acid 
malabsorption. Bile acids have antimicrobial activity and may lead to a relative abundance of 
Firmicutes at the expense of Bacteroidetes.(34) The underlying primary disease itself may 
also be associated with an altered microbiome such as in Crohn’s disease.(35-37)  
During the phase of intestinal adaptation, oral/enteral nutrition is initiated as soon as 
possible to stimulate intestinal function. Factors that may have an effect on the gut microbiome 
include the type and consequently composition of oral or enteral nutrition.(9, 10)  In addition, 
feeding tubes may act as loci for bacterial attachment and biofilm formation.(38, 39) If no 
enteral or oral nutrition is given, this has a substantial impact too. Ralls et al.(40) showed that 
enteral nutrition deprivation in patients undergoing small bowel resection (some receiving PN) 
led to overabundance of Proteobacteria.  
In patients with IF, antibiotics are often used to treat small intestinal bacterial 
overgrowth (SIBO) or central line-associated blood stream infections (CLABSI), which can 
influence the gut microbiome.(41-49) Next to antibiotics, other medications frequently used in 
IF such as proton pump inhibitors can also alter the gut microbiome.(50)  
 
3.2 Microbiome in patients with IF 
An overview of the results from studies looking at aspects of the gut microbiome in children 
and adults with IF or SBS is shown in Table 1 and 2. The primary aim of these studies was to 
characterize the gut microbiome composition in these patients. Almost all of these studies 
used 16S rRNA gene sequencing on fecal samples.  
3.2.1 Alterations in gut microbiome composition 
The most consistent finding among studies was an overall reduction in bacterial diversity.(33, 
51-54) However, Wang et al.(54) found that the global microbiome diversity, as evaluated by 
the Shannon index, in infants with SBS without complications [defined as intestinal failure-
associated liver disease (IFALD) or CLABSI] was similar to that of healthy controls. Apart from 
a reduction in bacterial diversity, several studies also reported a reduction in bacterial 
richness, the number of species representing the gut microbial community.(33, 54) The results 
of studies in children are in accordance with those in adults. 
Looking at compositional changes, most studies found a striking increase of Gram-
negative Proteobacteria, especially Gammaproteobacteria and their family 
Enterobacteriaceae (Figure 1, Table 3).(20, 33, 51, 53-55) In healthy people, Proteobacteria 
represent a very small proportion of the intestinal microbiome (1-2%) but in patients with IF 
these species become a dominant member of the community. The overabundance of 
Proteobacteria during treatment with PN may be due to lack of dietary fermentable substrate, 
such as fibre and resistance starch, in the gut lumen, necessary for growth of certain dominant 
species. This “gut starvation” effect and lack of inter-species competition offers the opportunity 
for subdominant species in the microbial community to increase over its dominant members.  
In addition, a depletion of Bacteroidetes was found(52-54, 56), and patients with IF 
presented low levels of Firmicutes of the order Clostridiales.(20, 33, 52) Another prominent 
difference from healthy controls is the overabundance of Bacilli, mainly Lactobacillus.(33, 51-
55, 57, 58) The increase in Lactobacillus is an important difference since in healthy subjects 
this group contributes less than 1% to the gut microbiome. The clinical significance of the 
increase in Lactobacillus remains unknown. One study reported that dominance of 
Lactobacillus plantarum spp was associated with a relatively long PN duration for which there 
is a possibility to wean off PN (i.e. successful intestinal adaptation)(33), while another study 
reported that this was associated with shorter PN duration.(53) Next to this, depletion of 
Lactobacillus was associated with poor growth.(20) Other studies found that high levels of 
Lactobacillus were associated with diarrhea(55) and certain strains may cause D-lactic 
acidosis.(57) Certain strains like Lactobacillus mucosae, were found in adults with SBS while 
this species has hardly ever been described in healthy humans.(52, 57) 
 
3.2.2 Alterations in microbiome functionality 
Little is known about the metabolic activity of the gut microbiome of patients with IF. A previous 
study in children with IF showed that the fecal concentration of acetate was lower in children 
with IF compared to healthy controls, while there was no difference in propionate, butyrate 
and total SCFA levels.(54)  
In adults with a jejuno-colic anastomosis, the abundance of Clostridium leptum and 
Clostridium coccoides, main butyrate-producing bacteria(59), was low.(52, 57) Other studies 
also found low levels of butyrate-producing bacteria in patients with IF(33, 58) or low levels of 
Firmicutes, known as major fibre fermenters.(20, 53, 56) Deficiency or depletion of these 
bacteria may affect the concentration of butyrate, a SCFA with established anti-inflammatory 
properties and a major energy substrate for the intestinal epithelium of the colon.(60, 61) 
However, in the aforementioned study, butyrate levels were not different in children with IF 
compared to healthy children.(54) A possible explanation for this might be that there is 
increased cross-feeding between acetate-producing and acetate-utilizing bacteria(62), hence 
acetate is utilized to produce butyrate(61), although more evidence is needed to confirm these 
findings. 
The only study that used shotgun metagenomics sequencing found differences in 
carbohydrate metabolizing genes between patients with SBS and healthy controls. The gut 
microbiome of children with SBS was deficient in genes needed for gluconeogenesis but 
enriched in branched and aromatic amino acid synthesis and citrate cycle pathways.(20)   
In addition to limitations pertinent to the laboratory methodologies used there are also 
limitations due to the lack of clinical metadata potentially affecting microbiome characteristics 
and a scarcity of published data exploring clinically important associations. For example, 
information about the amount and type of enteral/oral nutrition was often not reported. 
Because IF is a rare disease, most of the studies had small sample sizes and heterogeneous 
population characteristics. Most studies were of cross-sectional design and prospective 
studies assessing the microbial changes in patients with IF during the process of intestinal 
adaptation are lacking. Therefore, there is a need for large, international multicenter studies 
where successive data and samples will be collected prospectively from diagnosis and 
throughout the course of the disease.  
 
3.2.3 Difference between patients on PN versus patients who have successfully weaned off  
Patients with successful intestinal adaptation are able to stop PN, and therefore it is of interest 
to know if their gut microbiome is different compared to patients unable to wean off and healthy 
controls. This is particularly important to explore as it may offer an opportunity to use gut 
microbiome characteristics as prognostic biomarkers of intestinal adaptation or potentially 
manipulate gut microbial colonization with therapeutic interventions.  
Although it was not the primary objective of the current literature, some authors 
described differences of the gut microbiome between patients with IF on PN and patients 
weaned off. Engstrand Lilja et al.(51) found that microbiome diversity was significantly reduced 
in children with SBS on PN compared to children weaned off PN. However, the diversity in 
children weaned off was still lower than that of healthy controls. They also found that children 
on PN had a higher relative abundance of Enterobacteriaceae than children weaned off PN 
and controls. This is in line with the study of Korpela et al.(33), showing that most patients with 
a high abundance of Proteobacteria were still on PN and had received PN for a prolonged 
duration, while most patients with a high abundance of Clostridium cluster XIVa had weaned 
off PN several years earlier, and had been receiving PN for a limited time. Also Huang et 
al.(53) showed that Enterobacteriaceae was correlated with a longer PN duration whereas 
predominance of Lactobacillus was associated with a shorter PN duration. In contrast, Piper 
et al.(20) found that there was no significant difference in potentially pro-inflammatory bacteria 
belonging to Enterobacteriaceae between children on PN versus children weaned off.  
These early data suggest that patients with IF able to wean off PN have a gut 
microbiome more similar to healthy controls than patients unable to stop PN. However, 
analysis comparing patient characteristics between children weaned off PN versus children 
not able to wean off were not performed, probably due to the small sample sizes and high 
heterogeneity. Differences in the gut microbiome could also be due to reverse causality and 
availability of luminal nutrients for bacterial growth from initiation of enteral/oral nutrition. In the 
current literature, the duration of time that the patients had been weaned off PN was often not 
known and it is unknown if their diet was comparable to healthy controls.  
 
3.3 Gut microbiome in IF and clinical outcomes 
3.3.1 D-lactic acidosis 
Small intestinal bacterial overgrowth is a common complication in patients with IF, which has 
direct impact on morbidity and mortality(63, 64), and has been associated with dependence 
on PN.(65) Overgrowth of gram-positive anaerobes in the colon such as Lactobacilli, as well 
as poor metabolism of D-lactic acid and transfer in circulation can cause D-lactic acidosis. 
This is an unusual form of lactic acidosis in patients with SBS, which may lead to neurological 
symptoms.(66-68) Treatment includes antibiotics, correction of metabolic acidosis and 
restricting oral/enteral intake of carbohydrates.(69, 70) Recently, a case report has been 
published in which a 15-year old patient with SBS suffering from recurrent D-lactic acidosis 
was successfully treated with fecal transplantation.(71)  
 
3.3.2 Intestinal failure-associated liver disease 
Many factors have been implicated in the development for intestinal failure-associated liver 
disease (IFALD).(72-74) Recent studies suggest that decrease in microbial diversity and 
overgrowth of certain bacterial groups is associated with IFALD. Korpela et al.(33) showed 
that increased abundance of Proteobacteria was strongly associated with liver steatosis, portal 
and intestinal inflammation and liver fibrosis. The effect of the gut microbiome on liver steatosis 
in patients with IF was more predictive than the duration of PN or length of the residual 
intestine. Wang et al.(54) also showed that over-representation of Proteobacteria was 
common in children with IFALD. Many species belonging to Proteobacteria are opportunistic 
pathogens, such as E. coli. A possible mechanism by which Proteobacteria may induce liver 
injury is via gut derived lipopolysaccharide (LPS). LPS is a potent hepatotoxic inflammatory 
compound originating from gram negative bacteria in the gut microbiota, including 
Proteobacteria. It normally penetrates the intestinal mucosa in trace amounts, enter the portal 
circulation and become cleared in the liver. LPS has been involved in the pathogenesis of 
non-alcoholic fatty liver disease, leading to activation of toll-like receptors, promoting 
inflammation and fibrogenesis.(75, 76) It is therefore possible that the increased abundance 
on Proteobacteria in patients with IF in conjunction with a compromised  intestinal barrier 
function expose liver to higher, than normal, concentrations of LPS.(77-79) Another group of 
bacteria that may cause liver damage are species belonging to Lactobacillus which may 
promote liver steatosis via excessive bile acid deconjugation.(33)  
 
3.3.3 Poor growth 
Piper et al.(20) showed that, from a small number of participants, children with SBS and poor 
growth (defined as decline in their weight z score) had a depletion of the bacterial phylum 
Firmicutes compared to patients with SBS and good growth. However, the causal direction of 
this association is difficult to establish. It is possible that Firmicutes can harvest energy from 
fermentation of indigestible or malabsorbed nutrients and make it indirectly available to the 
host.(80) It is however equally possible that gut starvation from PN can deplete species that 
are dependent on the host’s diet, such as Firmicutes, although the caloric intake did not differ 
between children with poor versus good growth.  
 
4. Discussion 
4.1 The microbiome as a biomarker of disease management in patients with IF 
To date, there are no guidelines on the optimal timing for transition from PN to enteral nutrition 
and there is not an ideal marker to use at present.(3) In the case of IF patients on PN 
treatment, changes in the gut microbiome during gut adaptation may potentially be used as 
biomarkers to judge the optimal time of transition from PN to enteral nutrition. Prospective 
studies are required to assess longitudinal changes of the microbiome and their metabolic 
products in patients with IF undergoing gradual gut adaptation. The biomarker of choice to 
use in routine clinical practice should be quick to measure and the costs should be low. 
Current, yet limited, evidence suggests that SCFA are altered in patients with IF. Considering 
their dependency on host diet and speed and the low cost of measuring them, they may fulfil 
the criteria of a biomarker to dictate the timing of introduction and advancement of enteral 
nutrition. This hypothesis needs to be confirmed formally in well-designed prospective studies.  
Next to the use of the gut microbiome as a biomarker for intestinal adaptation and 
advancement of enteral nutrition, the microbiome might also be used to screen for risk of D-
lactic acidosis. Mayeur et al.(57) suggest that the D/L fecal lactate ratio seems to be a proxy 
index for changes in the microbiome of patients with SBS, and might be used to detect patients 
at risk of D-lactic acidosis. In a more recent study they reported that patients accumulating 
lactate in their feces had more lactate-producing bacteria and a lower proportion of lactate-
consuming bacteria, suggesting that the microbiome could be used to detect patients at risk 
of accumulation of lactate.(58)  
 
4.2 Microbial therapeutic interventions in IF 
The dysbiotic IF microbiome may be a therapeutic target for modulation. Potent interventions 
to manipulate the gut microbiome include the use of pharmacological doses of SCFA, 
prebiotics, probiotics, antibiotics and fecal transplantation.  
Since SCFA promote cell proliferation and differentiation of colonocytes, prevent 
growth of opportunistic pathogens and are key regulators of immune response (22, 28) it might 
be beneficial to use SCFA as a trophic factor to stimulate and promote intestinal adaptation. 
Previous studies in animals showed that supplementation of PN solutions with butyrate or 
mixed SCFA may enhance intestinal adaptation(81-84), an effect which is mediated by 
upregulation of glucagon like petide-2 (GLP-2)(85), an intestinal trophic peptide. However, the 
role of SCFA in this process is not always well established. In necrotizing enterocolitis, 
increased concentration of butyrate was associated with impaired barrier function, whereas in 
low levels it seemed to be of benefit to the host.(86) 
 Beyond the use of SCFA, a study in piglets showed that intestinal adaptation was 
stimulated by prebiotic or synbiotic supplementation.(87) Limited evidence suggests that 
synbiotics may increase fecal SCFA levels and fecal levels of Bifidobacteria, total facultative 
anaerobic bacteria, Enterobacteriaceae and Lactobacilli.(88) In a case report of a patient with 
SBS and recurrent episodes of neurologic dysfunction due to D-lactic acidosis, treatment with 
synbiotics was associated with a decline in D-lactate and the patient was free of recurrent 
episodes for 3 years without dietary restriction.(89) However, cases of bacteremia with 
prescribed probiotic bacteria in infants with SBS have also been reported.(90) Treatment with 
Lactobacillus rhamnosus had no effects on intestinal permeability, and was associated with a 
positive breath hydrogen test in a single patient.(91) Since the efficacy of probiotics in patients 
with SBS has not yet been adequately assessed, routine use of probiotics is currently not 
recommended in clinical practice.(92) The effect of fibre or prebiotic supplementation has not 
been explored in patients with IF on PN and might not be indicated in patients at risk of 
bacterial overgrowth.  
Fecal transplantation has been first developed for the treatment of patients with chronic 
Clostridium difficile infection after failure to respond to antibiotic therapy.(93) Recently, a child 
with SBS and recurrent, therapy resistant, D-lactic acidosis was successfully treated with fecal 
transplantation.(71) Fecal transplantation could therefore be a treatment alternative in 
selected patients with IF/SBS with dysbiosis and at risk of D-lactic acidosis. However, risks 
associated with fecal transplantation such as bacterial translocation and septic shock are 
currently unknown, as well as the duration of the effect.  
 
5. Conclusion 
Patients with IF have an altered gut microbiome and altered metabolic activity. Although the 
amount of literature is low, the current evidence is remarkably consistent. Despite differences 
in the primary pathology and underlying disease the effect of IF on gut microbiome is very 
similar with profound shifts with an increase of Proteobacteria, especially Enterobacteriaceae, 
and a decrease of Bacteroidetes and often Firmicutes. Bacterial diversity is remarkably 
decreased and there is high abundance of Lactobacillus. The changes found in children are 
in accordance with those in adults. Differences in microbiome characteristics have been found 
between patients on PN and those whose guts have adapted and have been weaned off PN. 
There is potential to use the gut microbiome as a biomarker to guide clinical practice during 
intestinal adaptation as well as a modifiable therapeutic target.  
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Figure legends 
 
Figure 1. Pie charts displaying the abundance of major bacterial phyla in patients 
with intestinal failure and healthy controls.  
Average proportions of each phylum were calculated from studies reporting results both 
in healthy controls and patients with IF.(53-55) in studies where results are reported in 
subgroups of patients with IF, average proportions were calculated first.  
 
Figure 2. Factors influencing the gut microbiome in patients with intestinal failure 
and its implications for clinical practice and future research. 
 
 
 
 
Table 1. Studies about the gut microbiome in children with intestinal failure  
Authors Participants Methods Findings 
Korpela et al. 
2017 
23 children with IF (median age 9.3 
years (IQR 4.6-17))  
- 17 weaned off PN  
 
58 healthy controls 
- 3 months old infants (n = 11) 
- 2 to 6 year old children (n = 35)  
- Adults (n = 12) 
Fecal samples 
Culture-independent 
phylogenetic  
DNA-based microarray 
analysis 
 ↓ diversity and richness 
 ↑ Lactobacilli, Proteobacteria and 
Actinobacteria, Clostridium clusters IX, XIII 
and XV, Fusobacteria, Spirochaetes 
 ↓ Clostridium clusters III, IV and XIVa  
 Liver steatosis : ↓ diversity and richness 
 Patients with steatosis from grade 0 to grade 
1:  ↑ Proteobacteria, Fusobacteria and low 
levels of Clostridium  
 Patients with moderate to severe steatosis 
(grade 2-3): ↑ Bacilli and Actinobacteria 
Wang et al.  
2017 
18 children with SBS (2-9 months) 
- All dependent on PN 
- 14 samples in IFALD group 
- 5 samples in CLABSI group 
Fecal samples 
16s rRNA sequencing  
Measurement of SCFA 
 ↓ richness in all SBS groups 
 ↓ diversity in IFALD and CLABSI group 
compared to asymptomatic SBS patients and 
healthy controls 
- 7 samples asymptomatic group 
7 healthy controls (4-10 months) 
 IFALD/CLABSI group: ↑ Proteobacteria, ↓ 
Actinobacteria compared to asymptomatic 
group 
 Lower levels of acetate in SBS groups, =  
propionate and butyrate and total SCFA 
Piper et al.  
2016 
 
8 children with SBS (0.7 – 11.3 years)  
- 3 weaned off PN 
- 3 with good growth 
- 5 with poor growth 
3 healthy controls (0.5 – 2.3 years) 
Fecal samples 
16s rRNA sequencing  
Metagenomics shotgun 
sequencing  
 
 
 ↓ Firmicutes order Clostridiales  
 Children with SBS and poor growth depletion 
of Firmicutes, expansion of 
Enterobacteriaceae 
 SBS/poor growth: deficient in genes needed 
for gluconeogenesis, enriched in branched 
and aromatic amino acid synthesis and citrate 
cycle pathway genes 
Davidovics et al. 2016 9 children with SBS (4 months to 4  
years) 
8 healthy controls (7-8 years) 
  
Fecal samples 
16s rRNA sequencing  
 Most dominant phyla Firmicutes, followed by 
Bacteroidetes, ↑ relative abundance of 
Proteobacteria and Gammaproteobacteria 
and Bacilli 
 Healthy controls ↑ Actinobacteria  
 Children with SBS and diarrhea ↑ 
Lactobacillus compared to children without 
diarrhea  
Engstrand Lilja et al.  
2015 
 
11 children with IF (1.5 – 7 years)  
- 6 weaned off PN 
7 healthy controls (siblings, 2- 13 
years) 
Fecal samples 
16S rRNA sequencing 
 ↓ bacterial diversity in children with SBS on 
PN versus children weaned off PN 
 Patients with suspected SIBO ↑ 
Enterobacteriaceae, patient on PN without 
suspected SIBO ↑ Lactobacillaceae 
CLABSI, central line-associated bloodstream infection; IF, intestinal failure; IFALD, intestinal failure-associated liver disease; PN, parenteral 
nutrition; SBS, short bowel syndrome; SCFA, short-chain fatty acids; SIBO, small intestinal bacterial overgrowth. Literature published after 
2000, case reports excluded. 
 
 
Table 2. Studies about the gut microbiome in adults with intestinal failure 
Authors Participants Methods Findings 
Gillard et al. 
2017 
17 adults with SBS  
- 9 lactate accumulating,  
- 7 non-lactate accumulating 
- 1 with recurrent D-lactic 
encephalopathy 
6 rats with SBS 
4 control rats 
Fecal samples  
Real-time quantitative PCR 
Pyrosequencing 
Measurement of SCFA 
 
 Most abundant phyla: Firmicutes, 
followed by Proteobacteria, 
Bacteroidetes and Actinobacteria  
 Lactate accumulating patients: ↓ total 
SCFA, ↓ propionate, = acetate and 
butyrate 
 Lactate-accumulating group: ↑ lactate 
producing bacteria, ↓ lactate-consuming 
bacteria 
Huang et al. 
2017 
5 adults with type II SBS 
5 adults with type III SBS  
- 2 patients weaned off PN  
5 healthy controls 
Fecal samples  
16s rRNA sequencing 
 
 
 ↓ diversity 
 Type II SBS: ↓ Firmicutes and 
Bacteroidetes, ↑ Proteobacteria 
compared to healthy controls 
 Type III SBS:  ↑ Bacteroidetes 
compared to healthy controls  
 Both type II and III: ↓ Lachnospiraceae, 
Ruminococcaceae, 
Peptostreptococcaceae, ↑ 
Enterococcaceae  
Boccia et al. 
2016 
12 adults with SBS  
16 healthy controls 
 
Fecal samples  
Culture-dependent method 
Quantitative real-time PCR 
 ↓ bacterial counts  
 ↓ Bacteroidetes, Firmicutes, 
Bifidobacterium and 
Methanobrevibacter Smithii  
Mayeur et al. 
2013 
16 adults with type II SBS 
- 9 lactate accumulating in feces 
- 7 non-lactate accumulating in 
feces 
Fecal samples  
Culture analyses and dominant bacterial 
groups were quantified by real time PCR 
Measurement of D and L-lactate levels in 
vitro cultures of bacterial strains and 
directly in fecal samples 
 Predominant bacteria: 
Lactobacillus/Leuconostoc, ↓ 
Clostridium and Bacteroidetes 
 No difference in Lactobacillus between 
lactate-accumulating and non-lactate 
accumulating group 
 Non-accumulator group ↑ Lactobacillus 
Mucosae 
Joly et al. 2010 11 adults with type II SBS Fecal samples and mucosal biopsies   ↓ diversity 
8 healthy controls Temporal temperature gradient gel 
electrophoresis 
Quantitative PCR 
 
 
 High prevalence of Lactobacillus  
 Poor diversity of Clostridium leptum, 
Clostridium coccoides and 
Bacteroidetes 
 Lactobacillus mucosae detected in 
patients,  not in healthy controls 
PN, parenteral nutrition; SBS, short bowel syndrome; SCFA, short-chain fatty acids. Literature published after 2000, case reports excluded. 
Based on the anatomy of the remaining intestine, SBS is frequently divided into three categories: end-jejunostomy (type 1), jejuno-colic 
anastomosis where the remnant jejunum is in continuity with part of the colon (type II), and jejuno-ileal anastomosis with ileocecal valve and 
intact colon in continuity (type III).2  
 
 
Table 3. Cumulative summary of findings of studies on gut microbiome in patients with 
intestinal failure 
Finding  Studies 
↓ Diversity Joly et al. 2010 47¶ 
Engstrand Lilja et al. 2015 46 
Huang et al. 2017 48 
Korpela et al. 2017 29¶ 
Wang et al. 2017 (in IFALD and CLABSI group) 49 
↓ Richness Huang et al. 2017 48 
Korpela et al. 2017 29¶ 
Wang et al. 2017 49 
↓ Total bacterial count Boccia et al. 2016 51 
↓ Number of species Wang et al. 2017 (in IFALD and CLABSI group) 49 
↑ Proteobacteria Davidovics et al. 2016 50 
Huang et al. 2017 (in SBS type II patients) 48 
Korpela et al. 2017 29 
Wang et al. 2017 (in IFALD and CLABSI group) 49  
↑ Gammaproteobacteria Davidovics et al. 2016 50 
↑ Enterobacteriaceae Engstrand Lilja et al. 2015 46¶ 
Piper et al. 2016 16 
Huang et al. 2017 (in SBS type II patients) 48  
Wang et al. 2017 (IFALD and CLABSI group) 49¶, † 
↓ Firmicutes Boccia et al. 2016 51 
Piper et al. 2016 16¶ 
Huang et al. 2017 (in SBS type II patients) 48 
↑ Bacilli/Lactobacillaceae/Lactobacillus Joly et al. 2010 47¶ 
Mayeur et al. 2013 52¶,† 
Davidovics et al. 2016 50 
Gillard et al. 2017 53¶,† 
Huang et al. 2017 48 
Korpela et al. 2017 29 
Wang et al. 2017 (in IFALD and CLABSI patients) 49† 
Detection of Lactobacillus mucosae Joly et al. 2010 47¶ 
Mayeur et al. 2013 52¶,† 
↑ Enterococcaceae Huang et al. 2017 48 
↑ Veillonellaceae Wang et al. 2017 (in asymptomatic and IFALD 
patients) 49† 
↑ Clostridium clusters IX, XIII and XV Korpela et al. 2017 29 
↓ Clostridium clusters III, IV, XIVa 
bacteria 
Korpela et al. 2017 29 
↓ Clostridiales Piper et al. 2016 16 
↓ Clostridium leptum, Clostridium 
coccoides 
Joly et al. 2010 47¶ 
↓ Lachnospiraceae Huang et al. 2017 48 
↓ Ruminococcaceae Huang et al. 2017 48 
↓ Peptostreptococcacae Huang et al. 2017 48 
↓ Erysipelotrichaceae Huang et al. 2017 48 
↓ Bacteroidetes Joly et al. 2010 47 
Boccia et al. 2016 51 
Huang et al. 2017 (in SBS type II patients) 48 
Wang et al. 2017 49† 
↑ Bacteroidetes Huang et al. 2017 (in SBS type III patients) 48 
↓ Actinobacteria Davidovics et al. 2016 50 
↑ Actinobacteria Korpela et al. 2017 29 
↓ Bifidobacterium Boccia et al. 2016 51 
↓ Methanobrevibacter Smithii Boccia et al. 2016 51 
↑ Fusobacteria Korpela et al. 2017 29 
CLABSI, central line-associated bloodstream infection; IFALD, intestinal failure-associated 
liver disease. Richness: Number of different species represented in gut microbiome; Diversity: 
A metric of species richness and their species evenness (i.e. how close in numbers each 
species is in a community). 
Based on the anatomy of the remaining intestine, SBS is frequently divided into three 
categories: end-jejunostomy (type 1), jejuno-colic anastomosis where the remnant jejunum is 
in continuity with part of the colon (type II), and jejuno-ileal anastomosis with ileocecal valve 
and intact colon in continuity (type III).2  
Only differences are reported. ¶ No p-values mentioned. † No comparison with healthy 
controls. 
 
